#United States #New Orleans #Alzheimer's Disease #28bio #CNS-3D Model

28bio Launches Next-Generation CNS-3D Induced Alzheimer's Model

In a significant stride towards combating one of the most challenging neurodegenerative diseases, 28bio has recently introduced the CNS-3D Induced Alzheimer's Model. This advanced brain organoid assay enables researchers to explore the therapeutic potential of new candidates aimed at ameliorating or halting Alzheimer's disease progression.

The Importance of Accurate Modeling

Despite the extensive research efforts into Alzheimer's, the development of effective therapies has faced daunting challenges, with a staggering 99% failure rate in clinical trials involving Alzheimer's-modifying therapies. Traditional models, including genetically engineered animal systems and conventional 2D cell cultures, often fall short of accurately mimicking human biology. Such inaccuracies have underscored the urgent need for more representative models that can effectively mirror the pathophysiology of Alzheimer's disease.

Features of the CNS-3D Induced Alzheimer's Model

The CNS-3D model stands out due to its use of human-derived neuroimmune organoids combined with exogeneous amyloid-beta oligomers. This setup facilitates an authentic recreation of key Alzheimer’s disease features, including amyloid-driven pathology, and evaluates neuronal function in a more nuanced environment.

According to Christopher Butt, PhD, Vice President of Technology at 28bio, “The CNS-3D Induced Alzheimer's Model unlocks a pathway for researchers to gain insights that are more aligned with human disease progression.” The model provides researchers with the capability to simulate complex neuroimmune interactions, dysfunction within neuronal networks, and the progression of tau pathology. This innovation marks a considerable advancement in the toolkit available to scientists for understanding the underlying mechanisms of Alzheimer's disease.

The Urgency of the Situation

Alzheimer’s disease is a rapidly growing concern, with projections hinting that the number of patients could exceed 111 million worldwide by the year 2050. This reality accentuates the necessity for predictive models that can expedite the creation of therapies that can alter the course of the disease significantly. “There has never been a more pressing time for advancing our understanding of Alzheimer’s pathology through innovative modeling approaches,” remarks Stuart Gibb, the Head of Business Development at 28bio.

The introduction of the CNS-3D Induced Alzheimer's Model adds to a suite of tools offered by the company, which includes CNS-3D Myelinated Organoids and CNS-3D Inflammatory Organoids. Together, these models empower a comprehensive understanding of neurodegenerative diseases, encompassing both pathogenesis and rehabilitation dynamics.

Availability and Future Prospects

The new CNS-3D model is set to begin shipping globally in the third quarter of 2026 and will also be accessible through CNS Services, expanding the reach of this pioneering technology. By employing these advanced models, researchers anticipate a new era in the development of Alzheimer’s treatments that can profoundly impact patient outcomes.

About 28bio

Founded with a mission to pioneer neurotechnology, 28bio leverages its Nexon™ platform, which integrates tissue engineering, neural interfacing, and AI. This innovative company is dedicated to addressing the neurological health crisis by enhancing the accuracy of predictive models for human therapies. Ethical standards remain at the forefront of 28bio's efforts as they advance their brain organoid technology, aspiring to revolutionize Alzheimer's research and treatment.

Conclusion

The launch of the CNS-3D Induced Alzheimer's Model heralds a new chapter in Alzheimer's research, providing a much-needed tool for evaluating therapeutic efficacy. As global populations age, addressing the Alzheimer's crisis becomes increasingly critical—making innovations from companies like 28bio vital to developing effective treatments that could alter the lives of millions suffering from this debilitating disease.